Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | HRH2 | P25021 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4780725 | 0.88 | SIGMAR1 (0.58) | SIGMAR1LMNAHRH2ALDH1A1POLB | |
| SCHEMBL10678985 | 0.86 | SIGMAR1 (0.58) | SIGMAR1LMNAALDH1A1POLBGAA | |
| SCHEMBL4844085 | 0.86 | SIGMAR1 (0.62) | SIGMAR1LMNAALDH1A1POLBGAA | |
| SCHEMBL4844073 | 0.86 | SIGMAR1 (0.62) | SIGMAR1LMNAALDH1A1POLBGAA | |
| SCHEMBL9582505 | 0.85 | SIGMAR1 (0.51) | SIGMAR1LMNAHRH2POLB | |
| SCHEMBL4778855 | 0.85 | SIGMAR1 (0.55) | SIGMAR1LMNAHRH2ALDH1A1POLB | |
| SCHEMBL31565134 | 0.84 | SIGMAR1 (0.48) | SIGMAR1 | |
| SCHEMBL9592739 | 0.84 | SIGMAR1 (0.60) | SIGMAR1LMNAALDH1A1 | |
| SCHEMBL7573297 | 0.84 | SIGMAR1 (0.56) | SIGMAR1LMNAALDH1A1POLB | |
| SCHEMBL24328 | 0.83 | SIGMAR1 (0.56) | SIGMAR1LMNAALDH1A1POLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10301267-B2 | Compounds | ASTRAZENECA AB (SE) | 2019-05-28 | — | — | US | disclosed |
| US-20170260143-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2017-09-14 | — | — | US | disclosed |
| US-9688640-B2 | Methods of treating cancer with a pyrazole derivative | ASTRAZENECA AB (SE) | 2017-06-27 | — | — | US | disclosed |
| US-20150299134-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2015-10-22 | — | — | US | disclosed |
| US-20140066455-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2014-03-06 | — | — | US | disclosed |
| US-8604022-B2 | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and salts thereof | ASTRAZENECA AB (SE) | 2013-12-10 | — | — | US | disclosed |
| EP-2139481-B1 | 1-[(2'-SUBSTITUTED)-PIPERAZIN-1'-YL]-ISOQUINOLINES AS NOREPINEPHRINE TRANSPORTER INHIBITOR THERAPEUTICS AND POSITRON EMISSION TOMOGRAPHY IMAGING AGENTS | UNIV MONTANA (US) | 2013-08-21 | — | — | EP | disclosed |
| EP-2139481-B1 | 1-[(2'-SUBSTITUTED)-PIPERAZIN-1'-YL]-ISOQUINOLINES AS NOREPINEPHRINE TRANSPORTER INHIBITOR THERAPEUTICS AND POSITRON EMISSION TOMOGRAPHY IMAGING AGENTS | UNIV MONTANA (US) | 2013-08-21 | — | — | EP | disclosed |
| CN-101611014-B | Amidopyrazoles as FGFR inhibitors | ASTRAZENECA AB | 2012-05-30 | — | — | CN | disclosed |
| US-20120129844-A1 | N-[5-[2-(3,5-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-3-YL]-4-(3,4-DIMETHYLPIPERAZIN-1-YL)BENZAMIDE AND SALTS THEREOF | ASTRAZENECA AB | 2012-05-24 | — | — | US | disclosed |
| US-7368449-B2 | 2-alkynyl- and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2008-05-06 | — | — | US | disclosed |
| US-20080076924-A1 | Piperazines as P2X7 antagonists | ABBOTT LABORATORIES | 2008-03-27 | — | — | US | disclosed |
| WO-2008005368-A2 | PIPERAZINES AS P2X7 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2008-01-10 | — | — | WO | disclosed |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION | 2004-11-04 | — | — | US | disclosed |
| US-5210193-A | Bactericide | AMERICAN CYANAMID COMPANY (US) | 1993-05-11 | — | — | US | disclosed |
| US-4940710-A | 7-(substituted)piperazinyl-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids | AMERICAN CYANAMID COMPANY (US) | 1990-07-10 | — | — | US | disclosed |
| US-4766125-A | N-aryl-piperazinealkanamides useful for protecting hearts from myocardial injury caused by ischaemia, anoxia or hypoxia | JANSSEN PHARMACEUTICA N.V. (BE) | 1988-08-23 | — | — | US | disclosed |
| EP-0230053-A2 | 7-(Substituted)piperazinyl-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids | AMERICAN CYANAMID COMPANY (US) | 1987-07-29 | — | — | EP | disclosed |
| EP-0068544-B1 | NOVEL N-ARYL-PIPERAZINEALKANAMIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 1987-06-03 | — | — | EP | disclosed |
| EP-0068544-A2 | Novel N-aryl-piperazinealkanamides | JANSSEN PHARMACEUTICA N.V. (BE) | 1983-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301267-B2 | Compounds | SLC10A1, CYP11B1, ABCB11 | SIGMAR1 2339/4885LMNA 2866/4885HRH2 3470/4885 |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | ADORA2A, ADORA3, ADORA1 | SIGMAR1 206/4885LMNA 4065/4885HRH2 42/4885 |
| US-20140066455-A1 | NOVEL COMPOUNDS | SLC10A1, ABCB11, CYP11B1 | SIGMAR1 1440/4885LMNA 3279/4885HRH2 3644/4885 |
| US-20120129844-A1 | N-[5-[2-(3,5-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-3-YL]-4-(3,4-DIMETHYLPIPERAZIN-1-YL)BENZAMIDE AND SALTS THEREOF | PKD1, SDHA, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | SIGMAR1 1058/4885LMNA 1590/4885HRH2 2857/4885 |
| US-20170260143-A1 | NOVEL COMPOUNDS | SLC10A1, ABCB11, CYP11B1 | SIGMAR1 1440/4885LMNA 3279/4885HRH2 3644/4885 |
| US-20080076924-A1 | Piperazines as P2X7 antagonists | P2RX7, P2RX1, P2RX2 | SIGMAR1 256/4885LMNA 2852/4885HRH2 502/4885 |
| US-20150299134-A1 | NOVEL COMPOUNDS | SLC10A1, ABCB11, CYP11B1 | SIGMAR1 1440/4885LMNA 3279/4885HRH2 3644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.